Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $431.88 million. The enterprise value is $324.91 million.
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 65.33 million shares outstanding. The number of shares has increased by 26.83% in one year.
| Current Share Class | 65.33M |
| Shares Outstanding | 65.33M |
| Shares Change (YoY) | +26.83% |
| Shares Change (QoQ) | +10.56% |
| Owned by Insiders (%) | 17.11% |
| Owned by Institutions (%) | 35.93% |
| Float | 50.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.17 |
| P/TBV Ratio | 4.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.30, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.30 |
| Quick Ratio | 18.95 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.52% and return on invested capital (ROIC) is -35.75%.
| Return on Equity (ROE) | -54.52% |
| Return on Assets (ROA) | -33.84% |
| Return on Invested Capital (ROIC) | -35.75% |
| Return on Capital Employed (ROCE) | -34.25% |
| Weighted Average Cost of Capital (WACC) | 12.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$958,793 |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EPRX has paid $30,202 in taxes.
| Income Tax | 30,202 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.02% in the last 52 weeks. The beta is 1.48, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | +53.02% |
| 50-Day Moving Average | 6.87 |
| 200-Day Moving Average | 6.92 |
| Relative Strength Index (RSI) | 51.60 |
| Average Volume (20 Days) | 435,847 |
Short Selling Information
The latest short interest is 4.60 million, so 7.04% of the outstanding shares have been sold short.
| Short Interest | 4.60M |
| Short Previous Month | 4.08M |
| Short % of Shares Out | 7.04% |
| Short % of Float | 9.14% |
| Short Ratio (days to cover) | 15.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.27M |
| Pretax Income | -44.46M |
| Net Income | -46.98M |
| EBITDA | -47.07M |
| EBIT | -47.27M |
| Earnings Per Share (EPS) | -$1.04 |
Full Income StatementBalance Sheet
The company has $138.88 million in cash and $2.01 million in debt, giving a net cash position of $136.87 million or $2.10 per share.
| Cash & Cash Equivalents | 138.88M |
| Total Debt | 2.01M |
| Net Cash | 136.87M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 136.19M |
| Book Value Per Share | 1.75 |
| Working Capital | 134.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.70 million and capital expenditures -$746,856, giving a free cash flow of -$33.44 million.
| Operating Cash Flow | -32.70M |
| Capital Expenditures | -746,856 |
| Depreciation & Amortization | 195,965 |
| Net Borrowing | n/a |
| Free Cash Flow | -33.44M |
| FCF Per Share | -$0.51 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |